NADAC acquisition cost data for AZITHROMYCIN 200 MG/5 ML SUSP. This is a generic medication, typically more affordable than brand-name equivalents.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 00093202631 | $0.2671 | 2022-12-21 | Rx |
| 24658070834 | $0.2671 | 2022-12-21 | Rx |
| 42806015134 | $0.2671 | 2022-12-21 | Rx |
| 43386047161 | $0.2671 | 2022-12-21 | Rx |
| 51672420003 | $0.2671 | 2022-12-21 | Rx |
| 59651000830 | $0.2671 | 2022-12-21 | Rx |
| 59762314001 | $0.2671 | 2022-12-21 | Rx |
| 70710146002 | $0.2671 | 2022-12-21 | Rx |
| 00093202694 | $0.3053 | 2022-12-21 | Rx |
| 42806015033 | $0.3053 | 2022-12-21 | Rx |
Generic: Azithromycin | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $69.9M | 8,152,125 | 5,916,068 | $1.22 |
| 2020 | $56.5M | 6,349,654 | 4,478,590 | $1.18 |
| 2021 | $53.3M | 5,981,011 | 4,273,552 | $1.16 |
| 2022 | $72.3M | 8,042,731 | 5,780,413 | $1.23 |
| 2023 | $59.6M | 8,259,537 | 5,970,026 | $0.9815 |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.